Elective Umbilical Hernia Repair in Patients With Cirrhosis
1 other identifier
interventional
51
0 countries
N/A
Brief Summary
Liver cirrhosis is a frequent and severe chronic disease. About 20 % of patients with liver cirrhosis develop umbilical hernias. In comparison, the prevalence in the general population is around 2 %. Patients with liver cirrhosis are often neglected and are not offered equal surgical treatments compared with other patient groups with chronic diseases due to fear of postoperative complications. The current literature is sparse, and many questions remain to be answered, such as timing of repair, risk profile, preoperative staging of the liver disease, possible optimization before surgery, repair technique, and postoperative care. Moreover, nationwide data are lacking. The management of umbilical hernias in patients with cirrhosis is debated. Recently, European Hernia Society published guidelines stating that elective hernia repair may be safe, and that emergency repair is associated with a high rate of morbidity and mortality. Nonetheless, surgeons remain reluctant to perform elective surgery on these patients due to fear of complications and mortality. The evidence supporting the guidelines is sparse and consists of small, low quality studies. One of the major concerns is that the existing studies failed to use clear and well-described definitions of the underlying severity of the liver disease. The rate of emergency repair may be much higher in patients with liver cirrhosis compared with the general population but there is no data available. The rate of emergency vs elective repair in patients with liver cirrhosis in Denmark is unknown, as well as the rate of reoperation for complications and readmission. Finally, we hypothesize that these patients may benefit from a more proactive approach with early diagnosis of their umbilical hernia by screening, preoperative optimization, and early elective hernia repair, but the effect of this hypothesis needs further evaluation.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Aug 2021
Typical duration for not_applicable
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 21, 2020
CompletedFirst Posted
Study publicly available on registry
December 29, 2020
CompletedStudy Start
First participant enrolled
August 1, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2023
CompletedApril 30, 2021
April 1, 2021
2.1 years
December 21, 2020
April 29, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
Serious Adverse Events
1. Death 2. Life-threatening adverse experience after surgery 3. Inpatient hospitalization or prolongation of existing hospitalization (for \> 24 hours) 4. Persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions
6 months after umbilical hernia repair and/or inclusion
Secondary Outcomes (1)
Adverse Events
6 months after umbilical hernia repair and/or inclusion
Study Arms (2)
Umbilical hernia repair
EXPERIMENTALPatients with cirrhosis undergoing umbilical hernia repair with or without preoperative optimization. See the section about interventions.
Watchful waiting
OTHERPatients who do not agree for operation but consent for follow-up. Patients will be followed in the whole inclusion period and can at any time change their preference if they wish to undergo surgery.
Interventions
Screening: All health professionals at the hospitals will participate in the screening of umbilical hernia. The screening will be done in the outpatient clinic, the Emergency Department and at the hospital wards.
Ascites will be drained using percutaneous drainage or PleurX. Diuretics be used to control ascites preoperative. Haemoglobin \< 5 mmol/L indicates the need for red blood cell concentrates using two dosage SAG-M (350-400 mL of red blood cell concentrates in each dose) will be done. Thrombocytopenia \< 150 10\^9/L will be treated with a TPO-analog using avatrombopag 40-60 mg dispensed as an intravenous fluid. Culture verified infection will be treated with specific antibiotics depending on the blood culture. International Normalized Ratio \> 1.7 will be treated with either phytomenadion, Octaplex or fresh frozen plasma depending on the INR.
A curved incision placed superiorly or inferiorly around the umbilicus. The umbilicus proper is retained in the skin flap. The blunt dissection is made to the hernia sac. The neck of the herniated sac is then dissected from adjacent tissues by a combination of blunt and sharp dissection. The edges of the fascial defect are measured and the fascial defect is closed with a non-absorbable running suture 2-0. A fitted lightweight polypropylene mesh is placed in an onlay fashion and fixed with 4-8 single non-absorbable sutures in the corners and at the midline, with a mesh overlap of at least 4 cm. The umbilicus is re-inserted with a single knot absorbable suture 3-0. Hemostasis is ensured. Skin closure is performed with Nylon suture 3-0. 20 ml bupivacaine 0.5% is injected to the fascia for early pain control.
Eligibility Criteria
You may qualify if:
- Patients must meet all the following criteria to be eligible to enrol in the study:
- Age ≥18 years and ≤80 years
- ASA I-III
- Patients with a diagnosis of liver cirrhosis
- Patients with a diagnosis of umbilical hernia (primary or recurrent umbilical hernia)
- Hernia defect size 0,5 cm - 6 cm, only one defect
- Patients who have given written informed consent to participate in the study after having understood this
You may not qualify if:
- Patients who cannot cooperate with the trial.
- Patients who cannot read and understand Danish.
- Alcohol- and/or drug abuse - to the discretion of the investigator.
- Fascial gap \> 6 cm
- Umbilical hernia repair secondary to another procedure
- Patients in dialysis
- Patients who meet one or more of following criteria on procedure day will not undergo surgery, but can undergo surgery at a later date if none of the criteria are fulfilled:
- ASA IV
- Culture verified infection within two weeks prior to umbilical hernia repair
- Anemia (Hgb \< 5?)
- International Normalized Ratio \> 1.7
- Thrombocytopenia (\<100 mill/mL)
- Large amount of ascitic fluid
- If the operation is considered too risky by any investigator, a patient can always be excluded from surgical intervention based on individual assessment.
- Patients presenting with complicated umbilical hernia (incarceration, rupture, strangulation or ulceration) and the need for acute surgical intervention.
- +1 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Medical student
Study Record Dates
First Submitted
December 21, 2020
First Posted
December 29, 2020
Study Start
August 1, 2021
Primary Completion
September 1, 2023
Study Completion
September 1, 2023
Last Updated
April 30, 2021
Record last verified: 2021-04
Data Sharing
- IPD Sharing
- Will not share